|
贺月华.生物制剂在免疫性肾小球疾病中的应用进展与临床实践[J].内科急危重症杂志,2026,32(4):347-352
|
| DOI：10.11768/nkjwzzzz.202608061046 |
| CN KeyWords: 生物制剂 免疫性肾小球疾病 靶向治疗 |
| EN KeyWords:Biologics Immune-mediated glomerular diseases Targeted therapy |
| Fund Project: |
| Author:HE Yue-hua |
| View Counts: 471 |
| PDF Download Counts: 328 |
| CN Abstract: |
| 摘要 免疫性肾小球疾病的治疗迎来生物制剂疗法的新时代。本文基于《免疫性肾小球疾病生物制剂治疗中国专家共识》及《改善全球肾病预后组织（KDIGO）2021肾小球疾病管理临床实践指南》，系统阐述生物制剂的分类与作用靶点，探讨生物制剂在常见免疫性肾小球疾病中的最新进展，旨在为临床实践提供参考。 |
| EN Abstract: |
| Abstract The treatment of immune-mediated glomerular diseases has entered a new era with the advent of biologic therapies. Based on the Chinese Expert Consensus on Biologic Therapy for Immune-Mediated Glomerular Diseases and the clinical practice guidelines for glomerular diseases issued by Kidney Disease: Improving Global Outcomes (KDIGO), this review systematically summarizes the classification and molecular targets of biologic agents. It further discusses recent advances in the application of biologic therapies in common immune-mediated glomerular diseases, with the aim of providing guidance for clinical practice. |
|
Full Text